Opexa Therapeutics Inc. (NASDAQ:OPXA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday.
According to Zacks, “Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company’s lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes. “
Several other brokerages have also recently weighed in on OPXA. Aegis raised their target price on Opexa Therapeutics to $11.00 and gave the company a “buy” rating in a research note on Monday, July 18th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Opexa Therapeutics in a research note on Sunday, July 3rd. Finally, Maxim Group reaffirmed a “buy” rating and set a $18.00 target price on shares of Opexa Therapeutics in a research note on Friday, August 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/10/opexa-therapeutics-inc-opxa-stock-rating-lowered-by-zacks-investment-research.html
Shares of Opexa Therapeutics (NASDAQ:OPXA) opened at 4.23 on Friday. The stock’s market cap is $29.82 million. The stock’s 50 day moving average price is $4.23 and its 200-day moving average price is $3.20. Opexa Therapeutics has a one year low of $1.69 and a one year high of $5.10.
Opexa Therapeutics (NASDAQ:OPXA) last announced its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. Opexa Therapeutics had a negative net margin of 324.97% and a negative return on equity of 109.48%. During the same period in the prior year, the firm posted ($0.56) EPS. On average, equities analysts predict that Opexa Therapeutics will post ($1.12) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Opexa Therapeutics stock. Renaissance Technologies LLC boosted its stake in Opexa Therapeutics Inc. (NASDAQ:OPXA) by 9.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,189 shares of the biopharmaceutical company’s stock after buying an additional 12,900 shares during the period. Renaissance Technologies LLC owned approximately 2.16% of Opexa Therapeutics worth $344,000 at the end of the most recent quarter. Institutional investors own 6.40% of the company’s stock.
About Opexa Therapeutics
Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.
Get a free copy of the Zacks research report on Opexa Therapeutics (OPXA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opexa Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.